Menu

Recent Interviews

Ryan Jackson, CEO, Newlox Gold Ventures Corp.

Ryan Jackson
CEO | Newlox Gold Ventures Corp.
60 Laurie Crescent, V7S 1B7 West Vancouver (CAN)

info@newloxgold.com

+1 778 738 0546

Newlox CEO Ryan Jackson on building a green gold producer with a rapid growth trajectory


Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


03. September 2020 | 13:50 CET

HAEMATO, MBH Corporation, USU Software - on the right path in 2020

  • Investments
Photo credits: pixabay.com

The year 2020 will be a special year. The Corona Pandemic has turned many industries upside down. The travel industry and restaurants, for example, have enormous challenges to overcome and many companies will not make it despite government support. However, there are also business models that have been able to continue despite the restrictions or have not experienced any significant impairments. The analysts of GBC Research have studied various companies and published their evaluations.

time to read: 2 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Sales and earnings growth achieved

HAEMATO AG is a listed specialty pharma company and focuses on growth markets of off-patent and patent-protected drugs. The main focus is on the therapy areas oncology, HIV/AIDS, neurology, cardiovascular and other chronic diseases. In the fast growing market of aesthetic medicine HAEMATO AG focuses on the largest market for private patients. The demand for inexpensive medications, which are delivered in highest quality and always meet the demand for reliable and comprehensive medical care, will continue to grow in the coming years as the life expectancy of the population increases.

In the first six months of 2020, the company achieved revenue growth of 23.2% from EUR 94.01 million in the previous year to EUR 115.81 million. As a result of the recent 10:1 capital reduction, the number of shares was reduced to 2.29 million (previously: 22.87 million). In line with the new number of shares and the company's recent performance, analysts at GBC Research have slightly lowered the target price per share to EUR 49.00 (previously: EUR 5.00), but continue to assign a BUY rating.

Fifth acquisition announced in 2020

MBH Corporation PLC is an investment holding company with subsidiaries in the construction, education, leisure and healthcare sectors. The group brings together well established and profitable small companies with a buy-and-hold perspective. Most of these subsidiaries were acquired through an exchange of shares by the company owners for new MBH shares. Given the favorable interest rate environment, MBH has also recently started to make loan-financed acquisitions. One example is the acquisition of Robinson's Caravans in 2020, which will be settled with a five-year loan with a final cash payment on maturity.

For future acquisitions, GBC Research's analysts have primarily assumed that the company will be financed under the bond program, which will result in an increase in debt with a corresponding increase in financial expenses. On the other hand, this will lead to a significantly lower dilution effect. Since the number of outstanding shares has increased significantly from 49.2 million to 61.4 million, the result of the DCF model is subject to a dilution effect. Although the fair enterprise value calculated by GBC increases from GBP 83.65 million to GBP 95.11 million, the fair value per share decreases inversely from GBP 1.70 to GBP 1.55 due to the higher number of shares.

Earnings forecasts and price target raised

USU Software AG and its subsidiaries develop and sell software solutions for knowledge-based service management. Its range of services includes solutions for strategic and operational IT & enterprise service management. Customers are provided with an overall view of their IT processes and IT infrastructure and are able to plan, charge, monitor and control services transparently. In the field of software license management, USU is one of the leading manufacturers worldwide.

The USU Group's international customer base now includes over 1,000 companies, including Allianz, Baloise Group, BOSCH, BMW, Daimler, Deutsche Telekom, DEVK, EDEKA, Heidelberger Druckmaschinen, Jacobs Engineering, Jungheinrich, Poste Italiane, Texas Instruments, VW, W&W and ZDF. In the first six months of 2020, USU Software AG achieved sales growth of 16.1% from EUR 44.88 million in the previous year to EUR 52.10 million, despite the current situation characterized by the Covid-19 pandemic. The analysts of GBC Research have reacted accordingly and increased the share price target from EUR 19.15 to EUR 22.00, but still maintain their 'HOLD' rating.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

25. November 2020 | 11:44 CET | by Nico Popp

Sartorius, Drägerwerk, Desert Gold: Vaccines for the portfolio

  • Investments

The crisis is on the home stretch. Several vaccines have been found and are about to be approved. But it will still take a while before the pandemic is defeated: millions of people need to be vaccinated. Usually, two doses of vaccine are required for this purpose, which must be administered at specific intervals. This Herculean logistical task must succeed in many countries if normality is to be restored. This much seems inevitable: 2021 will still be under the influence of the virus. Corona also leaves its mark on the capital market, whether directly or indirectly.

Read

25. November 2020 | 11:15 CET | by Stefan Feulner

Moderna, Triumph Gold, BioNTech - bet on winners!

  • Investments

Gold has not made it out - for the time being. Due to the decision of the Americans pro Joe Biden and the very successful developments regarding a vaccine against the coronavirus, the precious yellow metal went downhill for the time being. The correction may well continue a little further. However, in the past, these setbacks were lucrative with anti-cyclical entry opportunities. Therefore, one should use the time now to take a closer look at promising gold mines.

Read

24. November 2020 | 10:38 CET | by Stefan Feulner

BYD, BIGG Digital Assets, NEL ASA - Get rich with these trends!

  • Investments

Hydrogen, blockchain or e-mobility, these new technologies are currently keeping investors busy. Leading stocks from the respective industries have gained several hundred percent in the past months. But these trends are only at the beginning of their development. In addition to the top performers, second and third-tier companies with novel business models are gradually moving forward. Further outperformers seem preprogrammed.

Read